Physician profile
Maria E Baca
NPI 1679037923
$7,376.88
in general payments reported to CMS, 2019-2025
25 companies · $1,356 in 2025
The $1,356 reported for 2025 was more than what 91% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,301 · 2022: $1,385 · 2023: $1,821 · 2024: $1,513 · 2025: $1,356.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,473 · Travel and Lodging: $117 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,473.43 |
| Travel and Lodging | $117.30 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,858.94 | 2021-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,408.04 | 2022-2025 | Lifevest |
| Actelion Pharmaceuticals US, INC. | $923.62 | 2021-2023 | Opsumit, Uptravi |
| Astrazeneca Pharmaceuticals Lp | $376.46 | 2021-2024 | Wainua, Farxiga, Andexxa |
| Esperion Therapeutics, INC. | $294.61 | 2021-2024 | Nexletol |
| Janssen Pharmaceuticals, INC | $265.97 | 2021-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $258.19 | 2021-2023 | |
| Pfizer INC. | $257.97 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $246.18 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $242.38 | 2022-2025 | Verquvo, Winrevair |
| Medtronic, INC. | $216.34 | 2025 | Symplicity G3, Corevalve Evolut R |
| Penumbra, INC. | $158.91 | 2024 | Indigo System |
| Shockwave Medical, INC | $146.93 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $145.77 | 2022-2024 | Jardiance |
| Edwards Lifesciences Corporation | $145.42 | 2024-2025 | Evoque |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $128.08 | 2024 | |
| Abbott Laboratories | $101.87 | 2023-2025 | Amplatzer Amulet, Supera |
| Kestra Medical Technology Services, INC. | $79.41 | 2023-2024 | Assure Wcd |
| Impulse Dynamics (USA) INC. | $24.53 | 2024 | Optimizer |
| Inari Medical, INC. | $24.36 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Amarin Pharma, INC. | $18.57 | 2022 | |
| Kiniksa Pharmaceuticals, Ltd. | $17.03 | 2023 | Arcalyst |
| Recor Medical INC | $15.56 | 2024 | Paradise Renal Denervation System |
| Irhythm Technologies, INC. | $13.88 | 2022 | |
| Alydia Health | $7.86 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Baca listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.